الفهرس 
Chapter 1Only 14 pages are availabe for public view
 |  | from | 245 |  |  |
| | | from | 245 | | |
Abstract
HIV is a global health problem that can lead to death if left untreated. For the treatment of HIV, darunavir, a protease inhibitor and promising antiviral drug, is usually taken at a dose of 800 mg, along with ritonavir at a daily dose of 100 mg, which is used as a pharmacokinetic enhancer of darunavir to increase oral bioavailability. Lipid nanocarriers are a possible approach to enhance targeting of these two drugs to HIV reservoir sites, reduce required doses, and overcome pharmacokinetic challenges. In this thesis, solid lipid nanoparticles, nanoemulsions and hybrid lipid polymer nanoparticles were investigated as lipid nanocarriers for a mixture of darunavir and ritonavir in a ratio of (8:1). This thesis refers to the effect of different formulation factors that control the formation of new lipid-based nanocarriers containing Darunavir and Ritonavir. The results of this thesis are a promising indication for the design of oral nano-drug delivery systems that improve the bioavailability of these two drugs for the treatment of HIV.